Biotek-snakken — September 2024
-
Moberg Pharma lowers expectations on primary endpoint in ongoing phase 3 trial following data in a subset of patients
-
Der er gange i flere biotek i aften pga ESMO https://finance.yahoo.com/news/esmo-moderna-mrna-solid-tumour-101238212.html
-
-
Pfizer's BRAFTOVI + MEKTOVI Delivers Long-Term Benefits In BRAF V600E-Mutant NSCLC https://proinvestor.com/investornyt/1213639/pfizers-braftovi-mektovi-delivers-long-term-benefits-in-braf-v600e-mutant-nsclc
-
Bicycle Therapeutics Reveals Updated Clinical Results Across Oncology Pipelinehttps://proinvestor.com/investornyt/1213636/bicycle-therapeutics-reveals-updated-clinical-results-across-oncology-pipeline
-
Sutro Announces Updated Data From Phase 1b Study Of Luvelta Combination In Epithelial Ovarian Cancer https://proinvestor.com/investornyt/1213654/sutro-announces-updated-data-from-phase-1b-study-of-luvelta-combination-in-epithelial-ovarian-cancer
-
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher? https://proinvestor.com/investornyt/1213644/up-more-than-500-in-2024-can-instil-bio-keep-rocketing-higher
-
Penser Access & Future by Carnegie: Ascelia Pharma: Kassan fylld
Penser Access & Future by Carnegie: Ascelia Pharma: Kassan fylld
Fulltecknad företrädesemission Ascelia meddelade nyligen att bolagets företrädesmission blivit fulltecknad och bolaget kommer att tillföras en bruttolikvid om 105 mkr. Företrädesemissionen v...
MFN (mfn.se)
Aktiekurs 2,1 kr - Motiverat värde 5,0 - 7,0 kr.
-
Johnson & Johnson Reports Promising Interim Data From Phase 2 SunRISe-4 Study https://proinvestor.com/investornyt/1213975/johnson-amp-johnson-reports-promising-interim-data-from-phase-2-sunrise-4-study
-
I-Mab Reports Promising Results From Phase 1 Study Of Givastomig In Gastric Cance https://proinvestor.com/investornyt/1214486/i-mab-reports-promising-results-from-phase-1-study-of-givastomig-in-gastric-cancer
-
Incyte: Phase 2 Trial Results Of Niktimvo In Chronic Graft-Versus-Host Disease Meet Primary Goal https://proinvestor.com/investornyt/1215622/incyte-phase-2-trial-results-of-niktimvo-in-chronic-graft-versus-host-disease-meet-primary-goal
-
Saniona kommenterar godkännandet att inleda epilepsistudie https://www.biostock.se/2024/09/saniona-kommenterar-godkannandet-att-inleda-epilepsistudie/
-
https://saniona.com/newsroom/single-press-release/?slug=saniona-receives-regulatory-approval-for-san711-biomarker-study Saniona Receives Regulatory Approval for SAN711 Biomarker Study
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind